Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfizer Bivalent COVID-19 Vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Pfizer Bivalent COVID-19 Vaccine is a nucleoside-modified messenger RNA (mRNA) vaccine developed by Pfizer and BioNTech to provide protection against SARS-CoV-2. It is a bivalent formulation containing mRNA encoding the spike (S) protein of the original SARS-CoV-2 strain and mRNA encoding the spike protein of Omicron variants (either BA.1 or BA.4/BA.5). The vaccine utilizes lipid nanoparticle (LNP) technology to deliver the mRNA into host cells, where it is translated into the viral spike proteins. These proteins then trigger an adaptive immune response, including the production of neutralizing antibodies and the activation of T-cells. This specific vaccine is being evaluated in the BOOST-IC trial, led by Monash University, to determine optimized vaccination schedules and immunogenicity in immunocompromised populations who were largely excluded from initial registration trials.
- Brand names
- ComirnatyComirnaty Original/Omicron BA.1Comirnaty Original/Omicron BA.4-5
- Other names
- Pfizer-BioNTech COVID-19 Vaccine, Bivalenttozinameran + famtozinamerantozinameran + riltozinameran
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Pfizer Bivalent COVID-19 Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfizer Bivalent COVID-19 Vaccine.